SCHEMBL1735803

SCHEMBL1735803

CCCS(=O)(=O)N1C[C@@H](C(=O)O)N(c2ccc(F)cc2F)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.36
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
SCN9A Q15858 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
TP53 P04637 1/20 0.34
KDM4E B2RXH2 2/20 0.33
USP2 O75604 1/20 0.33
F10 P00742 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1737335 0.89 HTR7 (0.36) HTR7LMNASMN1; SMN2SCN9AL3MBTL1
SCHEMBL1735801 0.82 ACACB (0.36) HTR7LMNASMN1; SMN2L3MBTL1TP53
SCHEMBL1736512 0.78 GAA (0.40) LMNASMN1; SMN2SCN9AKDM4EGLA
SCHEMBL4214246 0.73 SLC6A9 (0.48) HTR7LMNASMN1; SMN2L3MBTL1KDM4E
SCHEMBL1737333 0.71 ACACB (0.38) HTR7LMNASMN1; SMN2TP53KDM4E
SCHEMBL9108982 0.67 P2RX7 (0.43) L3MBTL1HTT
SCHEMBL9108987 0.67 P2RX7 (0.43) L3MBTL1HTT
SCHEMBL21660807 0.63 HTT (0.43) L3MBTL1TP53POLBHTT
SCHEMBL11732823 0.61 ALDH1A1 (0.33) LMNAKDM4EALDH1A1POLB
SCHEMBL9893128 0.60 PER2 (0.48) HTR7L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 HTR7 2702/4885LMNA 1252/4885SMN1; SMN2 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.